alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 58 studies in Health systems and care delivery published 2023 (page 2 of 3) · 31,780 in the whole library · How the 0–100 score works

Download bibliography of these 58 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 17,251 studies have no institution on record and are not counted here.

What “Health systems and care delivery” covers

Health systems and care delivery — How health systems organize, coordinate and pay for dementia care, and where and how people with dementia actually receive it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Gridlock in hospital medicine

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Hospital Medicine 2023-12-12

Before the COVID-19 pandemic, supply and demand forcast models predicted significant nursing shortages across the United States through 2030 due to both an aging patient population and nursing workforce.1, 2 However, during the pandemic, we saw an exodus of younger nurses in addition to early retirements. 5 key findings →

Participants: 100 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of diagnosis timing on AD cost and healthcare utilization

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2023-12-01

Early-diagnosed patients (N = 421) have a lower utilization rate of inpatient skilled nursing facility, nursing home and hospitalization than late-diagnosed patients (N = 2817) after being diagnosed with AD. 5 key findings →

Design: case-control study Participants: 421 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Factors associated with delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation

✓ Peer-reviewed alzhub usefulness score 41 out of 100. European Heart Journal 2023-11-01

In this study on Medicare patients with AF, Black race, low-income subsidy, and dual eligibility were found to be associated with delayed OAC initiation, suggesting potential disparities in the care of AF with timely OAC treatment. 5 key findings →

Participants: 446,441 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of medication adherence quality measures for diabetes, hypertension, and hyperlipidemia with cognitive decline

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Family Medicine and Primary Care 2023-11-01

The study population of 99,774 individuals had a mean age of 71.0 years and was 49.1% female, 73.9% White, and 17.8% Black, with 62.0% living in an urban setting. 5 key findings →

Participants: 99,774 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Utilization and performance of long-term care system for older people with disabilities and dementia in Zhejiang Province, China

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in psychiatry 2023-04-11

To explore changes in performance, weaknesses, and utilization of the long-term care (LTC) system for older people with disabilities and dementia (OPWDD) in Zhejiang Province, China, thereby providing a reference for decision-making amid a progressively aging population. 2 key findings →

Participants: 1,000 Evidence: low

Full summary, score breakdown and related studies → Original source

HEDIS Measures for Geriatric Care Quality: Evidence, Equity, and a Governance Framework

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2023-01-30

The Healthcare Effectiveness Data and Information Set provides the dominant quality measurement framework for Medicare Advantage and commercial health plans, yet HEDIS lacks validated geriatric-specific quality indicators, equitable measurement standards for diverse older adult populations, and governance controls calibrated to the high-stakes Star Ratings financial incentive context. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessment for Alzheimer’s Disease Advancement Using Classification Models with Rules

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Applied Sciences 2023-11-08

Pre-diagnosis of common dementia conditions such as Alzheimer’s disease (AD) in the initial stages is crucial to help in early intervention, treatment plan design, disease management, and for providing quicker healthcare access. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterize demographics, comorbidities and co‐medications in newly diagnosed United States (US) Alzheimer’s Disease patients using Medicare claims

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Extensive understanding of a drug’s real‐world target population can inform generalizability of clinical trial results and highlight unaddressed risk. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Impact of fee-revision policy for gastrostomy on its implementation among older adults with dementia in Japan

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Public health 2023-12-21

This study aimed to evaluate the impact of the policy to reduce the reimbursement fee for percutaneous endoscopic gastrostomy (PEG) on the number of PEG procedures performed among older adults with dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

At Home versus in a Nursing Home: Long-term Care Settings and Marginal Utility

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Not indexed 2023

Marginal utility of financial resources when needing long-term care, and the related incentives for precautionary savings and insurance, may vary significantly by whether one receives care at home or in a nursing home. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Health Forum 2023-02-24

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Perceptions of Hospital Care for Persons With Dementia During the COVID-19 Pandemic: A Social Media Sentiment Analysis

✓ Peer-reviewed alzhub usefulness score 35 out of 100. The Gerontologist 2023-11-07

Hospital dementia care discourse on Reddit advanced 4 negative sentiment themes: (1) fear of poor medication management, hydration, and hygiene, (2) loss of patient advocacy, (3) precipitation of advance directive discussions, and (4) delayed discharge and loss of nursing home bed. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Using a newly validated algorithm to estimate prevalence and incidence of Alzheimer’s Disease and related dementias in Medicare claims

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2023-12-01

Using a fit‐for‐purpose validated algorithm, the 2019 annual prevalence and incidence of ADRD in the Medicare population aged 65+ with Part D enrollment was estimated to be 18% and 5.8% respectively. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Reduction of concurrent use of highly anticholinergic medications in an integrated healthcare system: 2018–2021

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of the American Geriatrics Society 2023-09-22

Being in the top 5% indicates that 95% of all other Medicare Advantage plans prescribed more Poly-ACH regimens than KPSC. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events